Skip to content
- ICMR and Panacea Biotec have started the Phase 3 clinical trial of DengiAll, India’s first indigenous dengue vaccine.
- This trial will evaluate the efficacy of India’s indigenous tetravalent dengue vaccine, DengiAll, developed by Panacea Biotec.
- The first participant in this trial was vaccinated at Pandit Bhagwat Dayal Sharma Post Graduate Institute of Medical Sciences (PGIMS), Rohtak.
- At present, there is no antiviral treatment or licensed vaccine for dengue in India.
- The tetravalent dengue vaccine strain (TV003/TV005) originally was developed by the National Institutes of Health (NIH), USA.
- ICMR and Panacea Biotec will conduct the Phase 3 clinical trial across 19 sites in 18 States and Union Territories of India.
error: Content is protected !!
